Search results
Results from the WOW.Com Content Network
Dexamethasone is commonly given as a treatment for croup in children. [25] A single dose can reduce the swelling of the airway to improve breathing and reduce discomfort. [25] Dexamethasone is sometimes injected into the heel when treating plantar fasciitis or heel pain, sometimes in conjunction with triamcinolone acetonide. There is no ...
In the high-dose 48-h DST, 2 mg of dexamethasone is given every 6 hours for 48 hours or a single dose of 8 mg is given. [8] This test is not needed if the 48-h low-dose DST has shown suppression of cortisol by over 30%. [8] These tests are based on the glucocorticoid sensitivity of pituitary adenomas compared to non-pituitary tumors. [8]
Low-dose and high-dose variations of the test exist. [4] The test is given at low (usually 1–2 mg) and high (8 mg) doses of dexamethasone, and the levels of cortisol are measured to obtain the results. [5] A low dose of dexamethasone suppresses cortisol in individuals with no pathology in endogenous cortisol production.
Tachyphylaxis: The acute development of tolerance to the action of a drug after repeated doses. [15] Significant tachyphylaxis can occur by day 4 of therapy. Recovery usually occurs after 3 to 4 days' rest. This has led to therapies such as 3 days on, 4 days off; or one week on therapy, and one week off therapy. Delivery-related adverse effects
For dogs, a dose ranges from 2.75 - 5.5 mg/kg once a day. The duration of treatment is usually at least five days, longer if there is a concurrent fungal or yeast infection. [4] Maximum duration of treatment is 30 days. [3]
Dexamethasone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. [1] In China, 999 Group sells it under the brand name Pi Yan Ping ...
The median effective dose is the dose that produces a quantal effect (all or nothing) in 50% of the population that takes it (median referring to the 50% population base). [6] It is also sometimes abbreviated as the ED 50, meaning "effective dose for 50% of the population". The ED50 is commonly used as a measure of the reasonable expectancy of ...
MDX-1097 (formerly called IST-1097, now called KappaMab) is a monoclonal antibody therapy that in 2023 has been assessed in a Phase IIb clinical trial in conjunction with lenalidomide and dexamethasone as a treatment for multiple myeloma, a type of white blood cell cancer.